Main takeout:
- Liquidia Corporation has been approved for Eurerpia for the treatment of PAH and PH-ILD.
- The company received a tentative approval last year.
The FDA has approved the Eurepian inhalation powder for the treatment of lung artery hypertension and pulmonary hypertension related to epilepsy lung disease.
“Today, we are now celebrating patients and doctors who can approach the potential of potential dry powder type treprostinil through excellent portable portability, tolerability, adequacy and durability. Roger Jeff Said in the release. “Through today’s milestones, our commercial teams are ready to start Yutrepia and make meaningful changes in the lives of patients who need help, and we expect to talk with doctors and patients for the unique benefits of Eurepia for the next few days and weeks.”
According to Liquidia, Eurerpia is the first and only preprostinil of treprostinil. Liquidia’s chief medical officer that the company can customize the design of the particles by formalizing the monopoly particle cloning of the non -sound point template technology. Rajeev Saggar, MD, Last year told Healio.
The approval was partially based on the results of the three -stage INSPIRE research, including 121 PAH patients. Yutepia (Yutrepia) seemed to be safe and introverted among patients.
The most common side effects related to Europe include cough, headaches, throat stimuli and dizziness.
Yutrepia was tentatively approved by the FDA last year, but the FDA was waiting for the regulatory monopoly of competing products to be completely approved.
As Healio reported earlier, the United Therapeutics complained about patent infringement of liquids. United Therapeutics was approved for the dry powder inhaler (TYVASO) to treat PAH and PH-ILD in May 2022.
According to Liquidia’s press release, the United Therapeutics has submitted consent to the temporary arrest and preliminary prohibition order to prevent Liquidia from firing yutrepia. The company participated in the verbal claim in the US District Court on May 20, 2025, and this consent is pending with the court.
Liquidia will host the webcast at 8:30 am on Tuesday, May 27, to discuss Eurefia’s commercial launch.
